A patient has undergone pioneering stem-cell therapy to treat Parkinson's disease, the Japanese drugmaker behind the ...

Juvmo, the brand name for tavapadon, became the 43rd entry on the FDA’s 2026 novel drug approvals list on September 25, 2026. AbbVie’s once-daily tablet is cleared for adults with Parkinson’s disease, ...

A University of Cincinnati study links weekly physical activity to slower cognitive decline and motor function loss in Parkinson's disease patients.

Parkinson's disease (PD) is a neurodegenerative condition that causes the progressive loss of dopamine-producing neurons in a ...

Deep brain stimulation, a process in which electrodes stimulate specific brain circuits to reduce motor symptoms, has long helped people with Parkinson’s disease manage their tremors — but a new ...

The San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or ...

In a large-scale double-blind trial where 410 early-stage Parkinson's patients were given 1g of nicotinamide riboside (NR) daily or a placebo for 52 weeks, no improvement in symptoms was observed, and ...

A Northwestern Medicine research lab has found a usually harmless virus in brain samples from Parkinson’s patients. The idea that Parkinson’s could be linked to a virus had been theorized for years, ...

This theory didn’t age well. A popular supplement commonly marketed for improving longevity failed to show meaningful ...

Older adults with autism were diagnosed with parkinsonism at more than double the rate of the general population, a study of ...

The treatment uses iPSCs obtained from healthy donors, which are developed into precursors of dopamine-producing neurons and transplanted into the brain to replace cells lost due to Parkinson's ...